{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Cancer&page=15", "query": { "condition": "Advanced Cancer", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 9795, "total_pages": 980, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Cancer&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Cancer&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T13:20:41.992Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00710736", "title": "A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "ARRY-334543, EGFR/ErbB2 inhibitor; oral", "type": "DRUG" }, { "name": "Capecitabine, 5-fluorouracil prodrug; oral", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Array Biopharma, now a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2008-06", "completion_date": "2011-04", "has_results": false, "last_update_posted_date": "2020-10-06", "last_synced_at": "2026-10-22T13:20:41.992Z", "location_count": 2, "location_summary": "Aurora, Colorado • Buffalo, New York", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00710736" }, { "nct_id": "NCT03042611", "title": "A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Cancer", "Gastric Adenocarcinoma" ], "interventions": [ { "name": "Rivoceranib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elevar Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 460, "start_date": "2017-03-14", "completion_date": "2020-09-23", "has_results": true, "last_update_posted_date": "2022-07-08", "last_synced_at": "2026-10-22T13:20:41.992Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Rogers, Arkansas • Detroit, Michigan + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Hawthorne", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03042611" }, { "nct_id": "NCT04246671", "title": "TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chordoma", "HER2-positive Breast Cancer" ], "interventions": [ { "name": "TAEK-VAC-HerBy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bavarian Nordic", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2020-08-10", "completion_date": "2024-12-11", "has_results": false, "last_update_posted_date": "2025-03-03", "last_synced_at": "2026-10-22T13:20:41.992Z", "location_count": 9, "location_summary": "Scottsdale, Arizona • Santa Monica, California • Jacksonville, Florida + 6 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04246671" }, { "nct_id": "NCT06855771", "title": "A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "BMS-986504", "type": "DRUG" }, { "name": "Izalontamab Brengitecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 182, "start_date": "2025-09-09", "completion_date": "2031-12-30", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-22T13:20:41.992Z", "location_count": 10, "location_summary": "Anchorage, Alaska • Boston, Massachusetts • Detroit, Michigan + 6 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06855771" }, { "nct_id": "NCT05159700", "title": "A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Advanced Solid Malignancies" ], "interventions": [ { "name": "PRJ1-3024", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zhuhai Yufan Biotechnologies Co., Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2022-03-31", "completion_date": "2026-06-29", "has_results": false, "last_update_posted_date": "2025-12-15", "last_synced_at": "2026-10-22T13:20:41.992Z", "location_count": 6, "location_summary": "Denver, Colorado • Orlando, Florida • Cincinnati, Ohio + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Austin", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05159700" }, { "nct_id": "NCT04882111", "title": "ALIGN Intervention in Patients With Advanced Cancer Discharging to a SNF", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "ALIGN", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2020-09-28", "completion_date": "2021-11-01", "has_results": false, "last_update_posted_date": "2021-11-11", "last_synced_at": "2026-10-22T13:20:41.992Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04882111" }, { "nct_id": "NCT05012371", "title": "Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Clear Cell Renal Cell Carcinoma", "Metastatic Clear Cell Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2022-02-16", "completion_date": "2027-10-25", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-22T13:20:41.992Z", "location_count": 3, "location_summary": "Tampa, Florida • Houston, Texas • Charlottesville, Virginia", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Houston", "state": "Texas" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05012371" }, { "nct_id": "NCT00151034", "title": "Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urologic Neoplasms" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2000-09", "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2015-01-21", "last_synced_at": "2026-10-22T13:20:41.992Z", "location_count": 11, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00151034" }, { "nct_id": "NCT06571734", "title": "XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Leiomyosarcoma", "Unresectable Leiomyosarcoma", "Bone Sarcoma", "Translocation-associated Soft Tissue Sarcoma", "Synovial Sarcomas", "Osteosarcoma Metastatic", "Ewing Sarcoma", "Ewing Sarcoma Metastatic", "Sarcoma Metastatic", "Sarcoma of Bone" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Zanzalintinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2024-09-19", "completion_date": "2033-07-01", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-22T13:20:41.992Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06571734" }, { "nct_id": "NCT00245102", "title": "Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Angiosarcoma", "Adult Epithelioid Sarcoma", "Adult Leiomyosarcoma", "Adult Malignant Fibrous Histiocytoma", "Adult Neurofibrosarcoma", "Adult Synovial Sarcoma", "Ovarian Sarcoma", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Uterine Sarcoma", "Stage III Adult Soft Tissue Sarcoma", "Stage III Uterine Sarcoma", "Stage IV Adult Soft Tissue Sarcoma", "Stage IV Uterine Sarcoma", "Uterine Carcinosarcoma", "Uterine Leiomyosarcoma" ], "interventions": [ { "name": "sorafenib tosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 147, "start_date": "2005-09", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2014-05-23", "last_synced_at": "2026-10-22T13:20:41.992Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00245102" } ] }